Tolerance and Efficacy of Rituximab in Sjogren's Disease

NCT00740948 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

122

Enrollment

OTHER

Sponsor class

Conditions

Sjogren's Disease

Interventions

DRUG: Rituximab (mabthera) Injection
DRUG: Placebo: NaCl 0.9% or Glucose 5%

Sponsor

University Hospital, Brest

Collaborators

[object Object]